抄録
The clinical study on the multiple myeloma, especially with respect to the effects of treatments was conducted in 101 patients with the multiple myeloma who had visited our hospitals for past 18 years. The results are summarized as follows: (1) The median age at the time for the diagnosis was 60, and the equal frequencies in men and women were obsereved. (2) Since 1975, the annual incidence and the number of patients with low tumor mas (Stage I by the criteria of Durie and Salmon) increased progressively. (3) Forty two patients with IgG myeloma were treated with previously reported regimens such as MP (5 cases), CP (16 cases), CUP (16 cases), and COP (5 cases). There was no significant difference between these four regimens with respect to the response rate, and the good response rate in total cases was 59.5%. (4) The good response rates in the patients with Stage I and II were 81.8% and 71.4%, respectively, while that of patients with Stage III was 54.5%. (5) The median survival in the evaluable sixty five patients was 40 months from the onset of symtoms; 31 months from the time for the first diagnosis; 30 months from the initiation of treatment. The patients in the early stage of the desease had a high value for the incidence of long survival. (6) The median survival, calculated from the time for the first diagnosis, was 27 months for IgG; 30 months for IgA; 22 months for BJP. (7) Survival had no difference between patients treated with BUN<30 mg/dl and patients treated with BUN≥30 mg/dl.
